Compare Abbott Laboratories (ABT) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Zillow Group Inc Class A — how do they compare? Abbott Laboratories trades at $95.58 (market cap $166.94B), while Zillow Group Inc Class A trades at $31.5 (market cap $7.50B). The key difference: Abbott Laboratories is far larger — about 22.3× Zillow Group Inc Class A's market cap, and Abbott Laboratories pays a 2.63% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| ABT | ZG | |
|---|---|---|
Market Cap | $166.94B | $7.50B |
Sector | Health | Media |
52-Week High | $136.62 | $86.76 |
52-Week Low | $82.57 | $29.14 |
Enterprise Value | $193.69B | $7.14B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Zillow Group (ZG) trades at $32.69, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $2.58 billion for 2025 with a net income of $23 million, marking a return to profitability after losses in prior years. Recent news is dominated by multiple securities class action lawsuits alleging anticompetitive conduct, creating significant headline risk.
The investment outlook is clouded by legal overhangs despite positive earnings beats and a consensus analyst price target of $57.80 implying substantial upside. Key risks include the outcome of litigation and the sustainability of recent margin improvements. The high P/E ratio of 131.8 suggests growth expectations are already priced in, demanding flawless execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
